Search Results
Sep 10, 2026, 07:30 ET TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection
against acute bacterial skin and skin structure infections (ABSSSI).The U.S. Food and Drug Administration has granted TNP-2092 Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations for the treatment of PJI. Additionally, TNP-2092 received the Excellence Award at
More news about: TenNor Therapeutics (Suzhou) Limited
Sep 10, 2026, 07:00 ET Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific cGMP manufacturing to support full commercialization.Media
More news about: Armata Pharmaceuticals, Inc.
Sep 10, 2026, 07:00 ET Health Canada Clears Updated Clinical Trial Protocol for Redsenol-1 Plus
NCI Drug Dictionary of the U.S. National Cancer Institute (NCI). Ginsenosides have attracted scientific interest because of their diverse biological activities."Cancer-related
More news about: Canada Royal Enoch Phytomedicine Ltd.
Sep 10, 2026, 07:00 ET Labcorp Highlights Strategic Priorities Driving Durable Growth and Shareholder Value at 2026 Investor Day
clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
More news about: Labcorp Holdings Inc
Sep 10, 2026, 05:37 ET Full-Life Technologies annonce l'obtention de l'autorisation IND de la FDA et de l'autorisation réglementaire australienne pour l'essai clinique de phase 1 sur le [²²⁵Ac]Ac-FL-261
base d'actinium et en phase clinique, a annoncé aujourd'hui que la Food and Drug Administration (« FDA ») a approuvé la demande de la Société relative à un nouveau médicament expérimental (« IND » - Investigational New Drug) de la Société concernant le [225Ac]Ac-FL-261 et que le programme
More news about: Full-Life Technologies
Sep 10, 2026, 03:26 ET /C O R R E C T I O N -- CordenPharma/
company's customers will also gain valuable access to integrated solutions from drug substance to drug products, leveraging CordenPharma's global facility network and expertise in manufacturing peptides (including oral peptide drug products), oligonucleotides, non-viral carriers such as LNPs, and small molecules,
More news about: CordenPharma
Sep 10, 2026, 02:48 ET /C O R R E C T I O N -- CordenPharma/
company's customers will also gain valuable access to integrated solutions from drug substance to drug products, leveraging CordenPharma's global facility network and expertise in manufacturing peptides (including oral peptide drug products), oligonucleotides, non-viral carriers such as LNPs, and small molecules,
More news about: CordenPharma
Sep 10, 2026, 01:47 ET Full-Life Technologies kondigt IND-goedkeuring van de Amerikaanse FDA en goedkeuring van de Australische regelgevende instanties aan voor klinische fase 1-studie naar [²²⁵Ac]Ac-FL-261
geïntegreerd, wereldwijd opererend radiofarmaceutisch bedrijf op basis van actinium in klinisch stadium, heeft vandaag aangekondigd dat de Amerikaanse Food and Drug Administration ("FDA") de aanvraag van het bedrijf voor onderzoek naar een nieuw geneesmiddel ("IND") voor [225Ac]Ac-FL-261 heeft goedgekeurd
More news about: Full-Life Technologies
Sep 09, 2026, 23:31 ET EMPE Diagnostics to Unveil CircuLOK Product Range at NATCON 2026, Expanding Access to TB Drug-Resistance Diagnostics
to select the resistance coverage they need, scale testing to demand, and deploy tests across the diagnostic network. The CircuLOK range for drug resistance testing is built around flexibility: laboratories can select the resistance panel that matches their patient population and budget, and expand
More news about: EMPE Diagnostics AB
Sep 09, 2026, 20:30 ET Insilico Medicine Doses First Patient in GENESIS-IPF-3, the World's First Phase III Trial of a Generative AI-Driven Innovative Drug
models to be evaluated in all tasks needed for drug discovery and launched state of the art (SOTA) foundation models outperforming other models and even internal tools in benchmarks. Using this new capability Insilico hopes to expand and accelerate longevity drug discovery and development both in terms of
More news about: Insilico Medicine
Sep 09, 2026, 17:14 ET Aardvark Therapeutics, Inc. (AARD) Investors with Substantial Losses Have Opportunity to Lead Aardvark Class Action Lawsuit Before October 13 Deadline
stock price plummeted over 56%. May 14, 2026: Aardvark announced that the U.S. Food and Drug Administration (FDA) placed a full clinical hold on its investigational new drug application (IND) for ARD-101, halting all ongoing studies under the IND, including the Phase 3 HERO trial and
More news about: Hagens Berman Sobol Shapiro LLP
Sep 09, 2026, 17:02 ET CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline
CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application (BLA), underscoring the ongoing regulatory
More news about: Hagens Berman Sobol Shapiro LLP
Sep 09, 2026, 16:53 ET Seismic Pharmaceuticals Announces the Enrollment of the First Patient in the Global Phase 3 Trial of Istaroxime in Cardiogenic Shock
treatments for heart failure. The company combines deep therapeutic expertise with a proven track record in acute heart failure drug development. Seismic Pharma's founding portfolio of drug candidates includes Seismic 101, a dual mechanism Na/K ATPase inhibitor and SERCA2a activator developed for acute and advanced
More news about: Seismic Pharmaceuticals
Sep 09, 2026, 16:47 ET PMI U.S. Expands ZYN Portfolio to Offer Adults More Smoke-Free Choices
authorized for sale in the United States following a comprehensive scientific review by the U.S. Food and Drug Administration (FDA). Subsequently, in June 2026, the FDA issued
More news about: PMI US Corporate Services, Inc.
Sep 09, 2026, 13:24 ET Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
HORIZON trial. The drug trial was reprotedly unsuccessful in demonstrating a benefit of pelacarsen over placebo in reducing the risk of cardiovascular events compared to placebo.Then, before the market opened on Tuesday, September 8, 2026, Novartis announced that its experimental drug, del-desiran,
More news about: SueWallSt.com
Sep 09, 2026, 13:18 ET CS Analytical and Lighthouse Instruments to Host Webinar on USP <382> Testing for Elastomeric Components and Systems
physicochemical testing now described in <381>, the new <382> chapter has expanded the scope to cover many functional aspects of drug packaging and delivery systems that incorporate an elastomeric component, including prefilled syringes and cartridges, while also expanding the types
More news about: CS Analytical
Sep 09, 2026, 13:02 ET Atman Health Wins ARPA-H Award to Build Agentic AI for Cardiovascular Care, Starting with Heart Failure
proven in medicine, yet in major patient registries only ~1 percent of eligible patients were on target doses of at least three of those foundational drug classes.Access to cardiologists compounds the problem. A 2024 analysis in the Journal of the American College of Cardiology found that 1,454
More news about: Atman Health, Inc.
Sep 09, 2026, 13:00 ET ARPA-H Selects UpDoc to Lead Development of Autonomous Clinical AI System, in an Initiative Joined by Microsoft, OpenAI and NVIDIA
failure, including managing medications, diet and exercise. The program's transformative goal is to create a first-of-its-kind, reliable, U.S. Food and Drug Administration (FDA) authorized clinical agentic AI system that serves around the clock as a new, digital member of a patient's clinical care team.
More news about: UpDoc
Sep 09, 2026, 12:56 ET Fewer Blood Components Transfused with fibryga® Than Cryoprecipitate, Secondary Analysis of Prespecified FIBRES Subgroups Reports
fibryga® should be evaluated in accordance with its current U.S. prescribing information.About the FIBRES trialThe U.S. Food and Drug Administration's approval of fibryga® for fibrinogen replacement in patients with acquired fibrinogen deficiency (AFD) was supported by the
More news about: Octapharma
Sep 09, 2026, 12:05 ET Global Action to End Smoking Awards Grant to University of Chicago to Increase Living Kidney Donation Through Smoking Cessation
aren't entirely safe, but they don't contain as many of the harmful chemicals found in cigarettes. Many health authorities, including the U.S. Food and Drug Administration and the UK's National Health Service, recognize the potential benefit of these tools for adults who smoke. The U.S. FDA has authorized
More news about: Global Action to End Smoking
Sep 09, 2026, 11:02 ET Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
uncovered a mechanism that had eluded prior investigators. PLA2G2D has long been characterized for its phospholipase activity, and previous efforts to drug the broader sPLA2 family, including terminated late-stage small-molecule programs for inflammation from major pharmaceutical companies, had assumed
More news about: Apeximmune
Sep 09, 2026, 10:31 ET Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
Loncastuximab tesirine (Lonca; ADC Therapeutics), and others.Iopofosine I-131 is Cellectar's lead investigational phospholipid drug conjugate (PDC) radiotherapeutic, developed to selectively deliver iodine-131 to tumor cells while limiting radiation exposure to healthy tissues. The
More news about: DelveInsight Business Research, LLP
Sep 09, 2026, 10:28 ET ImmunoGenesis Announces Appointment of Reza Mazhari and Mike Davis to Its Board of Directors
appointment of Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors. Dr. Reza Mazhari has more than 25 years of life science operating experience in drug discovery, early-stage clinical development and business and corporate development across diverse therapeutic areas including oncology. Mr. Davis brings
More news about: Immunogenesis Inc.
Sep 09, 2026, 10:07 ET REPL Deadline Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026
requires substantial evidence of effectiveness from an adequate and well-controlled clinical investigation under Section 505(d) of the Federal Food, Drug, and Cosmetic Act, 21 C.F.R. § 314.126, and Section 351 of the Public Health Service Act. The April 10, 2026 Complete Response Letter stated that RPL-001-16
More news about: Levi & Korsinsky, LLP
Sep 09, 2026, 10:05 ET UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact Levi & Korsinsky
one.Alleged Control Person LiabilityAuthority over the December 29, 2025 press release announcing resubmission of the OLC New Drug Application based on the original vendor's claimed "significant progress" toward regaining FDA complianceControl over annual and quarterly
More news about: Levi & Korsinsky, LLP